Literature DB >> 7867684

Elimination of fluconazole during continuous veno-venous haemodialysis (CVVHD) in a single patient.

K Wolter, G Marggraf, H Dermoumi, E Fritschka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7867684     DOI： 10.1007/bf02570511

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  The pharmacokinetics of fluconazole during haemodialysis in uraemic patients.

Authors:  S Oono; K Tabei; T Tetsuka; Y Asano
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Pharmacokinetics of fluconazole in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  D Debruyne; J P Ryckelynck; M Moulin; B Hurault de Ligny; B Levaltier; M C Bigot
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 3.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of fluconazole.

Authors:  D Debruyne; J P Ryckelynck
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

5.  An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole.

Authors:  S Toon; C E Ross; R Gokal; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335
  5 in total
  2 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Authors:  Michael A Veltri; Alicia M Neu; Barbara A Fivush; Rulan S Parekh; Susan L Furth
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.